Evidence is presented that bone marrow (BM) in addition to CD45 positive hematopoietic stem cells contains a rare population of heterogenous CD45 negative nonhematopoietic tissue committed stem cells (TCSC). These nonhematopoietic TCSC (i) are
Introduction
The concept of stem cell plasticity or trans-differentiation created a high degree of hope, excitement and somehow disappointment. The reason for this was an assumption that hematopoietic stem cells (HSC) isolated from relatively easily accessible sources such as bone marrow (BM), mobilized peripheral blood (mPB) or cord blood (CB) could be subsequently employed as precursors for other stem cells necessary for regeneration of various solid organs (eg heart, brain, liver or pancreas). Thus, excitement was raised in the scientific community after the first published data demonstrated a remarkable regenerative potential of 'HSC' in animal models of heart infarct, stroke and liver damage. [1] [2] [3] [4] Unfortunately, following the first exciting and promising reports, came some disappointment, when previously published data showing a contribution of 'HSC' to regenerate different tissues were not reproduced by other investigators. [5] [6] [7] [8] [9] In response to this the scientific community became polarized in their view on stem cell plasticity. These obvious discrepancies in the published results could be explained by (i) differences in tissue injury models employed, (ii) purity of stem cell populations used for regeneration, and (iii) problems in detection of tissue chimerism. 10, 11 Furthermore, in addition to these 'technical problems' some alternative explanations for the observed HSC transdedifferentiation have been proposed (Table 1 ).
The first concept that was rapidly accepted by the scientific community was explaining stem cell plasticity by phenomenon of cell fusion. [12] [13] [14] [15] Accordingly, data were presented that donorderived HSC or monocytes may fuse with differentiated cells in recipient tissues which leads to the creation of daughter cells that have a double number of chromosomes in their nuclei and express cell surface and cytoplasmic markers that are derived from both parental cells. Another explanation of stem cell plasticity is based on a possibility of the appearance of epigenetic changes in cells exposed to external stimuli (eg organ damage, unphysiological culture conditions or stress). Both cell fusion and epigenetic changes, however, are extremely rare and randomly occurring events that may not fully account for the previously published positive 'trans-dedifferentiation' data. Furthermore, fusion as a major contributor to the observed donor-derived chimerism was excluded in several recently published elegant studies. [16] [17] [18] [19] [20] In all of these deliberations concerning stem cell plasticity, the concept that BM may contain heterogeneous populations of stem cells was surprisingly not taken carefully enough into consideration. We postulate that the regeneration studies that show contribution of donor-derived HSC to tissues without excluding this possibility by including the proper controls could lead to wrong interpretations. Thus, the presence of heterogeneous populations of stem cells in BM tissue should be considered first before experimental evidence is interpreted simply as trans-differentiation/plasticity of HSC. In this review, we will present evidence that BM cells are heterogeneous.
Could stem cells be 'plastic'?
The therapeutic cloning experiments clearly demonstrated that DNA of even terminally differentiated somatic cells may become 'dedifferentiated' to a 'virgin-type' DNA, as those seen in nuclei of early embryonic stem cells. 21 This process requires, however, the presence of enzymes that dedifferentiate DNA (eg demethylases, histone processing enzymes), which are present in the cytoplasm of the oocyte. It is not proven yet if similar enzymes could be expressed/induced in more differentiated stem cells. In contrast, it seems very likely that several mechanisms exist in stem cells that prevent the phenomenon of trans-dedifferentiation to occur. This process, could lead to uncontrolled neoplastic transformation of stem cells.
On the other hand, it had been suggested that the genome of stem cells is in an open/accessible status and therefore are more susceptible for potential dedifferentiation events. [22] [23] [24] [25] For example, it had been postulated that HSC expressing mRNA for multiple lineages exist in BM as a continuum and undergo cell-cycle-related conversions before being locked into organspecific fate. [23] [24] [25] If a similar phenomenon applies to other BM nonhematopoietic stem cells is not clear at this moment.
Regardless of these theoretical deliberations direct proof for trans-dedifferentiation of HSC in vivo has not been provided yet. All data generated so far are based on indirect evidence from studies which demonstrated stem cell plasticity in various experimental models.
Contribution of BM-derived cells in tissue/organ regeneration
Contribution of BM, mPB or CB cells that were infused or locally delivered to damaged tissues for organ regeneration was explained by the phenomenon of stem cell trans-dedifferentiation. On the other hand, the failure of these cells to regenerate organs was immediately interpreted by the opponents of stem cell plasticity as evidence that this phenomenon does not exist at all.
The effectiveness of stem cells in regeneration/functional improvement of damaged organs/tissues may depend on the appropriate experimental model employed. However, the involvement of other nonplastic mechanisms (Table 2) should be taken into consideration. Accordingly, improvement in organ regeneration after delivery of BM-, mPB-or CB-derived cells could rely on the presence of endothelial precursors among the grafted cell population, that improves vascularization of damaged tissues, 26 or by secretion of proangiopoietic factors by the infused cells. 27 In fact our previous work demonstrated that early hematopoietic stem/progenitor cells secrete several proangiopoietic factors. 28 The most controversial effect, however, is a beneficial possibility of the so-called 'therapeutic cellfusion'. 29 It is very likely that all of these processes listed in Table 2 may all together contribute in various degrees to tissue regeneration, depending on the model of organ injury.
Developmental migration of stem cells
Early embryogenesis is the most active period for the developmental migration/trafficking of stem cells. With the beginning of gastrulation and organogenesis stem cells migrate to places where they establish rudiments for new tissues and organs. At certain points of development stem cells colonize tissue-specific niches, where they reside as a population of self-renewing cells, which supplies new cells that effectively replace senescent ones or those undergoing apoptosis. Thus the role of stem cells in adult life is restricted to maintain a proper cell turnover in the given organ or tissue.
Accumulating evidence suggests that stem cells may also actively migrate/circulate in the postnatal period of life. Stem cell trafficking/circulation may be one of the crucial mechanisms that maintains a pool of stem cells dispersed in stem cell niches of the same tissue, that are spread throughout different anatomical areas of the body. This phenomenon is very well described for HSC, 30 but other tissue committed stem cells (TCSC) for example, endothelial, skeletal muscle, skeletal or neural stem cells are probably circulating as well. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] BM -home of migrating stem cells It is well recognized that BM develops by the colonization of stem cells that migrate/circulate in the peripheral blood. Accordingly, by the end of the second trimester of gestation, HSC leave the major hematopoietic organ which at this point of ontogenesis is the fetal liver and began to colonize the developing BM tissue. Signals for the translocation of HSC from the fetal liver to BM, is provided by the alpha chemokinestromal-derived factor-1 (SDF-1) that is secreted by osteoblasts lining the developing marrow cavities, marrow fibroblasts and endothelial cells. In response to SDF-1 HSC that express its specific seven transmembrane-span G protein-coupled CXCR4 receptor leave the fetal liver and began to home into BM, where they finally establish adult hematopoiesis. [45] [46] [47] [48] [49] It is very likely that at this point BM is also colonized by several other TCSC that may circulate during organogenesis and rapid body growth/expansion. To support this all TCSC express CXCR4 receptor on their surface and follow an SDF-1 gradient. 34, 38, [50] [51] [52] [53] [54] [55] Thus the SDF-1-CXCR4 axis alone or in combination with other chemoattractants plays a crucial role in accumulation of TCSC in developing BM. These cells find in BM a permissive environment to survive, and what we believe may play an underappreciated role as a reserve pool of stem cells for organ/tissue regeneration during postnatal life ( Figure 1 ). We envision that these nonhematopoietic stem cells were responsible in several reported studies for the occurrence of donorderived chimerism after systemic infusion or local delivery of BM-derived cells.
Evidence that tissue damage triggers circulation of TCSC
Evidence is provided that during organ damage TCSC are mobilized from the BM, and perhaps other tissue-specific niches into peripheral blood, where they circulate in order, what we believe, to 'home' to damaged tissues and participate in tissue repair. [34] [35] [36] [37] [38] [39] [40] [41] 56 It is well documented that damaged tissues upregulate expression of several chemoattractants of TCSC. In addition to SDF-1, also other factors such as VEGF, HGF/SF, LIF or FGF-2 are upregulated in damaged organs. Hypoxiaregulated/induced transcription factor (HIF-1) plays an important role in expression of several of these factors. To support this notion promoters of SDF-1, VEGF and HGF/SF contain functional HIF-1 binding sites. 57, 58 We noticed that the number of circulating TCSC in peripheral blood could be increased by some mobilizing agents for example, G-CSF in combination with compounds that block Table 1 Alternative explanations of the phenomenon of stem cell plasticity Table 2 Potential contributions of stem cell infusion to organ/tissue regeneration . Thus the process of stem cell mobilization from BM into PB should be envisioned not only as a process that mobilizes HSC but also as a process that mobilizes some BM-residing TCSC. The question remains how big is the regenerative potential of these mobilized/circulating cells; however, we believe that these cells may efficiently regenerate some small tissue injuries. Another important consequence of stem cell circulation in peripheral blood is their potential competition for organ-/tissue-specific niches ( Figure 1 ). This explains, for example, why heterogeneous populations of stem cells could also be detected in various organs (eg HSC in muscle tissue).
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BM stem cells are heterogeneous
The concept that BM may contain some nonhematopoietic stem cells was postulated by several investigators. Furthermore, we believe the best evidence that BM stem cells are in fact heterogeneous was provided by experiments that demonstrated their 'plasticity'.
To demonstrate that BM in addition to HSC also contains an admixture of CXCR4 þ TCSC, which accumulate there during development in response to SDF-1, transwells were employed to isolate these cells from a suspension of bone marrow mononuclear cells (BMMNC). By employing this chemotactic isolation strategy to an SDF-1 gradient, we were able to isolate a population of mobile CXCR4 þ cells that are highly enriched in mRNA for the markers for early TCSC. [34] [35] [36] [37] [38] [39] [40] [41] In fact, we noticed that cells are enriched for mRNA for early skeletal muscle (Myf-5, MyoD, Myogenin), heart muscle (Nkx2.5/Csx, GATA-4, MEF-2C), neural (Nestin, GFAP), liver (CK19, a-fetoprotein), intestinal epithelium (Nkx 2-3, Tcf4, CDX1, Msi1h), skin epidermis (Trp63, Krt 2-6a, Krt 2-5, BNC) and endocrine pancreas (Nkx6.1, Pdx1, Ptf1) markers. Furthermore, we also confirmed previously reported data that BM may contain a population of mobile endothelial TCSC. 26, 43 More importantly, we noticed that CXCR4
þ BMMNC are not only highly enriched for mRNA for TCSC, but we could also detect by immunohistochemical staining the presence of cells that express proteins characteristic for TCSC such as: Myf-5, nestin, Nkx2.5/Csx and GATA-4. 38 In in vitro cultures they can also differentiate into cardiomyocytes and form neurospheres (Figure 2A and B) . 38 Of note CXCR4 Since BM contains heterogenous populations of TCSC, our data explain, without invoking the concept of HSC plasticity, why several investigators were able to demonstrate in vitro cultures the appearance of skeletal muscle, liver, pancreatic or neural cells growing from plated BM-, mPB-or CB-derived cells.
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Separation of BM-derived HSC from TCSC
Since both HSC and TCSC express CXCR4, it was obvious that by employing chemotactic isolation to an SDF-1 gradient, we will isolate from BMMNC both CXCR4 þ HSC and nonhematopoietic stem cells. Thus to separate both of these populations of stem cells, we stained them with antibodies against panhematopoietic antigen CD45 and subsequently sorted CD45 þ and CD45 À cells by FACS ( Figure 3) . In subsequent experiments, we noticed that murine SDF-1-responsive, CXCR4
þ CD45 þ cells grow hematopoietic colonies in vitro, and form spleen colonies in vivo in lethally irradiated recipients, and most importantly radioprotect animals from lethal irradiation. 38, 40, 41 At the same time SDF-1-responsive CXCR4 þ CD45 À cells do not show any of the above described effects, but in contrast to CXCR4 þ CD45 þ cells are very highly enriched in mRNA and proteins for TCSC. Thus by employing chemotactic isolation to SDF-1 followed by FACS sorting for expression of the CD45 antigen we could efficiently separate HSC from TCSC ( Figure 3 ). Our further research demonstrated that in mice we can also separate HSC from TCSC by employing multiparameter sorting. Accordingly, while HSC were found in a population of 38, 40, 41 In humans both HSC and TCSC express CXCR4 and are CD34 þ and AC133 þ . Similarly as in mice, we stained these cells with antibodies against panhematopoietic marker CD45 antigen and found that human HSC are CD45 þ in contrast to TCSC that are CD45
À . Thus, in humans we can sort from BMMNC a population of CXCR4
À cells that is enriched for TCSC (Figure 3 ). An important implication from these studies is that antigens that were considered for years as classical markers for HSC such as CD34 þ and AC133 þ are also expressed on nonhematopoietic TCSC as well.
BONE MARROW OTHER TISSUES
-HEART -PANCREAS -EPITHELIUM -ENDOTHELIUM LIVER NEURAL TISSUE SKELETAL MUSCLE Figure 1 Concept that CXCR4 þ TCSC circulate in the body and may compete for occupancy of SDF-1-positive niches in various tissue/ organs. Hematopoietic, skeletal muscle satellite, liver oval, neural and other tissue-specific stem/progenitor cells (eg for retina or renal tubular epithelium) express CXCR4 and circulate at low levels in the peripheral blood to maintain stem cell pools in distant parts of the body. BM tissue as a source of SDF-1 and many other stem cell chemoattractants (eg HGF/SF, VEGF, KL, LIF, FGF-2) and survival factors provides an environment that encourages circulating CXCR4 þ TCSC to home into it. In this context BM tissue becomes a 'home' or 'hideout' not only of hematopoietic stem cells but also of already differentiated circulating TCSC and perhaps PSC as well. TCSC may also compete for stem cell niches in various organs and may explain why heterogeneous populations of stem cells can be also detected in various tissues. The number of TCSC in the peripheral blood increases during tissue damage (eg heart infarct, stroke) or pharmacological mobilization (eg G-CSF, T140). The involvement of these other tissuespecific chemoattractants to SDF-1 may explain why circulating TCSC have a higher affinity for stem cell niches in the organs for which they are committed.
Heterogenous populations of stem cells in bone marrow M Kucia et al
We hypothesize that TCSC would also be present in the so-called side population of BMMNC, and stain low with Hoe33342, Pyronin and Rh123. 83 Staining with anti-CD45 antibodies could be subsequently helpful in the next step to separate them into a population of HSC and TCSC.
Morphological and functional analysis of TCSC
By employing different identification strategies we noticed that TCSC are very small cells (B5-7 mM in diameter) and the nuclei of some of these cells contains DNA that by electron-microscopic analysis resembles DNA seen in embryonic stem cells (manuscript in preparation). This suggests that TCSC could be enriched in a population of pluripotent stem cells (PSC). Furthermore, the fact that TCSC are very small should be taken in consideration, especially in protocols based on gradient or velocity centrifugation employed to isolate stem cells from BM, mPB and CB. We postulate that it is very likely that the majority of TCSC because of their very small size could be lost during those isolation procedures. 
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Moreover, we noticed that TCSC are highly mobile and respond to an SDF-1 gradient, adhere to fibronectin and fibrinogen, and may interact with BM-derived stromal fibroblasts. 40, 41 Time laps studies revealed that these cells attach rapidly to, migrate beneath ( Figure 2C and Supplemental video online) and undergo emperipolesis in marrow-derived fibroblasts. Since fibroblasts secrete SDF-1 and other chemottractants they may create a homing environment for small CXCR4 þ TCSC. This robust interaction of TCSC with BM-derived fibroblasts has an important implication -suggesting that isolated BM stromal cells may be from the beginning 'contaminated' by these tiny cells. We will return to this important observation again, while discussing the apparent 'plasticity' of marrow-derived fibroblastic cells, for example, mesenchymal stem cells (MSC) or multipotential progenitor cells (MAPC).
TCSC are in fact a very rare cell population among BMMNC. We found that approximately one cell in 10 . 40 The number of these cells is higher in young animals, and their number decreases with age ( Figure 4) . Furthermore, TCSC are barely detectable in 1-year-old mice, which correspond to a 50-year-old human. 38 This age-dependent content of TCSC in BM may explain why regeneration processes are more efficient in younger individuals.
We also noticed differences in the content of these cells among BMMNC between long-and short-living mouse strains. 40 Our preliminary data show that the concentration of these cells in much higher in BM of long living (eg C57Bl6) as compared to short-living (DBA/2J) mice. It would be interesting to identify genes that are responsible for tissue distribution/expansion of these cells. These genes could be involved in controlling the life span of mammals.
BM as a 'home' of a heterogenous population of nonhematopoietic CD45
À stem cells
As mentioned above, we postulate that the best evidence for the heterogeneity of BM stem cells is supported by experiments that demonstrated their apparent 'plasticity'. In addition, several other studies provided direct evidence that BM stem cells are heterogenous and perhaps pluripotent. [84] [85] [86] [87] For example, BM was found to contain endothelial-, 26 bone-, 31,88 skeletal muscles- 34 and cardiac-TCSC. 38 Interestingly, those endothelial-, skeletal muscle and cardiac-TSC were found to be CXCR4 þ CD45 À . In addition a population of Sca-1 þ kit À CD45 À cells with a potential of multilineage differentiation 85 and a population of nonhematopoietic CD34 þ CD45 À cells that are able to grow in vitro myogenic and endothelial colonies and contributed in vivo to regeneration of damaged muscle tissue were also recently identified in murine BM (Sato et al. Blood 2004; 104: 194a-195a, abstract 677). These cells are CD45
À , however, they were not phenotyped for CXCR4 expression. The potential list of versatille stem cells identified in BM is continuously expanding. To support this notion it is widely accepted that BM-derived adherent/fibroblastic cells are enriched in nonhematopoietic CD45
À MSC and MAPC. [89] [90] [91] [92] [93] [94] [95] The origin of these cells and their relationship to other BM CD45 À cells, however, is still not fully elucidated. 
Heterogenous
CD45
À MSC and MAPC -are they members of TCSC/PSC family?
Generally, the phenomenon that cells derived from in vitro colonies of BM-derived fibroblasts, called Colony Forming Units of Fibroblasts (CFU-F), may accumulate under certain culture conditions calcium and fat and potentially give rise to bone, cartilage or fat tissue was reported more than 40 years ago. 96, 97 This phenomenon was surprisingly very recently 'rediscovered' and interpreted as a result of plasticity of MSC. 90 Thus in the light of this new publication, CFU-F-derived BM fibroblasts were renamed MSC. Unfortunately approaches based on serial passages of these cells or cultures initiated at low concentrations failed to identify MSC at the single-cell level. Interestingly, in the meantime a new population of even more primitive stem cells was described in cultures of intensively replated BM-derived fibroblasts. These cells are called MAPC. 91, [93] [94] [95] Similarly, as MSC, MAPC have not been isolated yet and identified at the single-cell level. Surprisingly, both MSC and MAPC, that similarly as BM-derived fibroblasts are of mesodermal origin, were found to be able to cross germ layer boundaries and to differentiate in vitro into neural cells (ectoderm) or liver cells (endoderm). 95 Furthermore, MSC and MAPC were reported to be also 'plastic' in vivo and able to regenerate several organs in animal models (eg heart, spinal cord, liver). [98] [99] [100] Recently, however, some doubts accumulated around the concept of marrow-derived fibroblastic cells being 'plastic' precursors of versatile tissue-specific stem cells. First, some elegant studies demonstrated that the neural differentiation of fibroblasts is probably an in vitro artifact that depends on morphological changes of these cells induced during their culture in neural-differentiating media. 101, 102 Fibroblasts cultured in these conditions mimic neurons, but in fact it is only an in vitro morphological artifact. Second, some evidence accumulated that BM can contain TCSC for the skeleton that are in fact distinct from BM-derived fibroblasts or MSC. 88, 103 In a recently published paper, it was suggested that these osteoblastic TCSC, and not marrow fibroblasts were in fact responsible for the therapeutic effects after transplantation of BM-derived cells in children with osteogenesis imperfecta. 88 Furthermore, a very similar phenomenon of calcium or fat accumulation in cultured cells was reproduced in our laboratory with several nonfibroblastic cell lines (eg rhabdomyosarcomas and lung cancer) if these cells were cultured in the appropriate 'differentiating media' (not published). Thus an important question emerges, if calcium or fat accumulation in cultured marrow fibroblasts is merely an effect of the pathological calcification or steatosis of cells that are exposed in vitro to high concentrations of hydrocortisone, calcium phosphate etc. We believe that it is rather an in vitro epigenetic phenomenon and not necessarily a process that is initiated at the stem cell level.
We cannot, however, exclude the possibility that the cultures that are initiated from BM-derived adherent cells/fibroblasts, contain an admixture of TCSC. On the other hand, it is also possible that by employing purification strategies described in this review (Figure 3) , we isolate along with TCSC a population (subpopulation?) of cells that were described as MSC or MAPC. Thus, it is very likely that we are calling similar/overlapping populations of nonhematopoietic CD45
À stem cells residing in BM by different names. These cells, however, due to the differences in their isolation procedures and delay in phenotypical analysis, which is required for their expansion, may display different surface antigens. To support this notion, while MSC and MAPC are phenotyped after prolonged in vitro expansion/passages, TCSC are identified/purifed from a suspension of BMMNC 'freshly' isolated from BM by employing surface markers that are expressed on these cells while they reside under 'steady-state conditions' in marrow tissue. Furthemore, our observation that TCSC may hideout in fibroblasts ( Figure 2C ) support that TCSC could be coisolated together with BM fibroblasts. Based on this assumption, we hypothesize that TCSC and not fibroblasts themselves were in fact responsible for 'germ layer trans-dedifferentiation' observed in MSC or MAPC cultures.
Interestingly, however, the fibroblastic cells present in MSC and MAPC cultures were reported to be CXCR4 negative, a recent observation suggests that a small population of BM-derived fibroblast responds to a SDF-1 gradient and express CXCR4 on their surface. 104, 105 If these cells are potential CXCR4
þ TCSC for mesenchymal tissue requires further studies. 
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We speculate that these cells could be a 'missing link' between TCSC/PSC and MSC/MAPC.
However, the origin of MSC/MAPC has not been solved yet, other new candidate cells with properties similar to MSC/MAPC were recently reported to be present in human cord blood and described as 'unrestricted somatic stem cells' (USSCs) 106 and BM as 'marrow-isolated adult multilineage inducible cells' (MIAMI). 107 In addition, the poorly identified population of the so-called 'spore like' stem cells with an ability for multipotent differentiation was also recently identified in murine BM. 86 We speculate that all of these CD45 À stem cells (TCSC/PSC, MSC/MAPC, USSC and MIAMI cells) could be somehow related. It is possible that these rare nonhematopoietic CD45
À stem cells, due to the differences in the experimental approaches employed for their isolation and identification, were assigned different names. Thus, it would be challenging to investigate in the future the possibility that perhaps we are looking on the same population of CD45 À stem cells that reside in BM from different experimental angles.
Therapeutic implications for TCSC
One can ask, if BM really contains heterogeneous TCSC, than why is there still such a controversy about the role of BMderived cells in tissue/organ regeneration. There are several answers to this question (Table 3) . First, the number of these cells among BMMNC is very low (1 cell in 10 3 -10 4 of BMMNC). Furthermore, these cells are present in BM of young mammals and their number decreases with age. In addition, they may play a role only in regeneration of small tissue injuries. Heart infarct or stroke could be considered as severe tissue disasters, in which these cells do not have much possibility to reveal their full potential. Second, the allocation of these cells to the damaged areas depends on homing signals that may be inefficient in the presence of some other cytokines or proteolytic enzymes that are released from damaged-tissue-associated leukocytes and macrophages. We can envision, for example, that metalloproteinases released from inflammatory cells may degrade SDF-1 locally and thus perturb homing of CXCR4 þ TCSC. Third, in order to reveal the full potential of these cells, as reported in some positive 'plasticity' studies, they have to be fully functional. We cannot exclude the possibility that these cells, while residing/being 'trapped' in the BM, are not fully functional or remain 'locked' in a dormant state and need the appropriate activation signals by unidentified factors. Finally, we cannot exclude that in some cases these cells could be attracted to inflammatory areas, and if not properly incorporated into the damaged tissue they may transform and initiate tumor growth. Such a possibility was suggested in a recently published report. 87, [108] [109] [110] Mankind is searching for a key to longevity and there is no doubt that stem cells could be an important answer to this problem. Thus, there is a need for a reliable source of stem cells and adult TCSC could potentially provide a real-therapeutic alternative for embryonic stem (ES) cells and therapeutic cloning. Thus in this time of ethical debates on the application of ES cells in therapy, the potential of TCSC should be tested. We have to answer if they really could be efficiently employed in the clinic or if they are merely some developmental remnants in BM. The following years will bring an important answer to these questions. Scientists are on the search for a key to longevity and already crossed the Rubicon. Alea iacta estyy.
